1
|
Alcaraz A, Rodriguez-Cairoli F, Colaci C, Silvestrini C, Gabay C, Espinola N. Lung cancer in Argentina: a modelling study of disease and economic burden. Public Health 2024; 232:86-92. [PMID: 38759472 DOI: 10.1016/j.puhe.2024.03.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Revised: 03/05/2024] [Accepted: 03/20/2024] [Indexed: 05/19/2024]
Abstract
OBJECTIVES Lung cancer remains a significant global public health challenge and is still one of the leading causes of cancer-related death in Argentina. This study aims to assess the disease and economic burden of lung cancer in the country. STUDY DESIGN Burden of disease study. METHODS A mathematical model was developed to estimate the disease burden and direct medical cost attributable to lung cancer. Epidemiological parameters were obtained from local statistics, the Global Cancer Observatory, the Global Burden of Disease databases, and a literature review. Direct medical costs were estimated through micro-costing. Costs were expressed in US dollars (US$), April 2023 (1 US$ = 216.38 Argentine pesos). A second-order Monte Carlo simulation was performed to estimate the uncertainty. RESULTS Considering approximately 10,000 deaths, 12,000 incident cases, and 14,000 5-year prevalent cases, the economic burden of lung cancer in Argentina in 2023 was estimated to be US$ 556.20 million (396.96-718.20), approximately 1.4% of the total healthcare expenditure for the country. The cost increased with a higher stage of the disease, and the main driver was drug acquisition (80%). A total of 179,046 disability-adjusted life years could be attributable to lung cancer, representing 10% of the total cancer. CONCLUSION The disease and economic burden of lung cancer in Argentina implies a high cost for the health system and would represent 19% of the previously estimated economic burden for 29 cancers in Argentina.
Collapse
Affiliation(s)
- A Alcaraz
- Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
| | - F Rodriguez-Cairoli
- Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
| | - C Colaci
- Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
| | - C Silvestrini
- Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
| | - C Gabay
- Independent Consultant in Oncology, Buenos Aires, Argentina.
| | - N Espinola
- Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
| |
Collapse
|
2
|
Giorlando M, Gabay C, Mendoza L, Mari E, Escorial C, Schnetter L, Ortega E, Andreasyan A. 149P Gender differences in non-small cell lung cancer: A comparative analysis of European and Asian patients. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00403-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
3
|
Finckh A, Tellenbach C, Herzog L, Scherer A, Moeller B, Ciurea A, von Muehlenen I, Gabay C, Kyburz D, Brulhart L, Müller R, Hasler P, Zufferey P. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. RMD Open 2021; 6:rmdopen-2020-001174. [PMID: 32385143 PMCID: PMC7299517 DOI: 10.1136/rmdopen-2020-001174] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Revised: 02/11/2020] [Accepted: 03/02/2020] [Indexed: 01/11/2023] Open
Abstract
Background Multiple biologic and targeted synthetic disease-modifying rheumatic drugs (b/tsDMARDs) are approved for the management of rheumatoid arthritis (RA), including TNF inhibitors (TNFi), bDMARDs with other modes of action (bDMARD-OMA) and Janus kinase inhibitors (JAKi). Combination of b/tsDMARDs with conventional synthetic DMARDs (csDMARDs) is recommended, yet monotherapy is common in practice. Objective To compare drug maintenance and clinical effectiveness of three alternative treatment options for RA management. Methods This observational cohort study was nested within the Swiss RA Registry. TNFi, bDMARD-OMA (abatacept or anti-IL6 agents) or the JAKi tofacitinib (Tofa) initiated in adult RA patients were included. The primary outcome was overall drug retention. We further analysed secondary effectiveness outcomes and whether concomitant csDMARDs modified effectiveness, adjusting for potential confounding factors. Results 4023 treatment courses of 2600 patients were included, 1862 on TNFi, 1355 on bDMARD-OMA and 806 on Tofa. TNFi was more frequently used as a first b/tsDMARDs, at a younger age and with shorter disease duration. Overall drug maintenance was significantly lower with TNFi compared with Tofa [HR 1.29 (95% CI 1.14 to 1.47)], but similar between bDMARD-OMA and Tofa [HR 1.09 (95% CI 0.96 to 1.24)]. TNFi maintenance was decreased when prescribed without concomitant csDMARDs [HR: 1.27 (95% CI 1.08 to 1.49)], while no difference was observed for bDMARD-OMA or Tofa maintenance with respect to concomitant csDMARDs. Conclusion Tofa drug maintenance was comparable with bDMARDs-OMA and somewhat higher than TNFi. Concomitant csDMARDs appear to be required for optimal effectiveness of TNFi, but not for bDMARD-OMA or Tofa.
Collapse
Affiliation(s)
- A Finckh
- Department of Internal Medicine Specialties, University Hospitals Geneva, Geneva, Switzerland
| | - C Tellenbach
- Statistics Group, SCQM Foundation, Zurich, Switzerland
| | - L Herzog
- Statistics Group, SCQM Foundation, Zurich, Switzerland.,Zurich University of Applied Sciences, Institute of Data Analysis and Process Design (IDP), Winterthur, Switzerland
| | - A Scherer
- Statistics Group, SCQM Foundation, Zurich, Switzerland
| | - B Moeller
- Inselspital und Universitätsspital Bern, Bern, Switzerland
| | - A Ciurea
- University Hospital Zurich, Zurich, Switzerland
| | | | - C Gabay
- Department of Internal Medicine Specialties, University Hospitals Geneva, Geneva, Switzerland
| | - D Kyburz
- Department of Rheumatology, University Hospital Basel, Basel, Switzerland
| | - L Brulhart
- Rheumatology, Réseau hospitalier neuchâtelois, La Chaux-de-Fonds,Switzerland
| | - R Müller
- Kantonsspital Aarau, Aarau, Switzerland
| | - P Hasler
- Kantonsspital Aarau, Aarau, Switzerland
| | - P Zufferey
- Centres Hospitaliers Universitaires Vaudois, Lausanne, Switzerland
| | | |
Collapse
|
4
|
Giorlando M, Mansilla D, Morgado PC, Gabay C, Castro M. P19.05 Postoperative Recurrence of Early-Stage Non-Small Cell Lung Cancer (NSCLC): Clinical Outcomes of Oligo versus Poly-recurrence Disease. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
5
|
Gabay C, Castro M, Bonet M. P48.16 Network Meta-Analysis of ICI for Extensive Small-Cell Lung Cancer (ESCLC) as Upfront Therapy. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
6
|
Tsou F, Angel M, Reinhold F, Gabay C, Bonet M, Bluthgen M, Minatta J, Bustos B, Novas C, Rizzo M, Kowalyszyn R, Cundom J, Richardet E, Ferreira G, Bradley DG, Roa G, Tatangelo M, Caglevic C, Pini A, Paskevicius M, Flores M, Pupareli C, Martin C. P21.13 Durvalumab in Locally-Advanced NSCLC in LATAM: Real World Data from Patients Included in the Early Access Program. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Burkhard J, Ciurea A, Gabay C, Hasler P, Müller R, Niedrig M, Fehr J, Villiger P, Visser LG, de Visser AW, Walker UA, Hatz C, Bühler S. Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals. Vaccine 2020; 38:3610-3617. [PMID: 31911033 DOI: 10.1016/j.vaccine.2019.12.042] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2019] [Revised: 12/11/2019] [Accepted: 12/19/2019] [Indexed: 02/03/2023]
Abstract
BACKGROUND The live-attenuated yellow fever vaccine (YFV) is generally contraindicated in immunosuppressed patients. Our aim was to investigate if immunosuppressive therapy impairs the long-term protection against yellow fever virus in patients who had received YFV prior to the start of their immunosuppressive therapy. METHODS Our study examined 35 healthy individuals and 40 immunosuppressed patients with autoimmune diseases or organ transplants. All individuals had received YFV prior to the onset of their immunosuppression. We analysed the long-term influence of the immunosuppressive therapy on the YFV protective immunity by measuring neutralising antibodies (NA) with the Plaque Reduction Neutralisation Test (PRNT). We assessed risk factors for a negative PRNT result (titre below 1: 10) and their influence on the magnitude of the NA. RESULTS A median time interval of 21.1 years (interquartile range 14.4-31.3 years) after the YFV in all patients, a total of 35 immunosuppressed patients (88%) were seropositive (PRNT ≥ 1:10) compared to 31 patients (89%) in the control group. The geometric mean titres of NA did not differ between the groups. The duration of an underlying rheumatic disease was the only risk factor found for a lower magnitude of NA. An insufficient level of NA was found in nine subjects (12%) who had received a single dose of YFV (in one subject, the number of YFV doses was unknown). CONCLUSION The use of an immunosuppressive drug started after the administration of the YFV did not affect long-term persistence of NA. A second dose of YFV may be necessary to secure long-term immunity.
Collapse
Affiliation(s)
- J Burkhard
- Department of Public Health / Division of Infectious Diseases, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
| | - A Ciurea
- Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland
| | - C Gabay
- Division of Rheumatology, University Hospital of Geneva, Geneva, Switzerland
| | - P Hasler
- Department of Rheumatology, Cantonal Hospital Aarau, Aarau, Switzerland
| | - R Müller
- Division of Rheumatology, Department of Internal Medicine, Cantonal Hospital St. Gallen, St. Gallen, Switzerland; Division of Rheumatology and Clinical Immunology, Department of Internal Medicine Ludwig-Maximilians-University Munich, Germany
| | - M Niedrig
- Robert Koch-Institut (RKI), Berlin, Germany
| | - J Fehr
- Department of Public Health / Division of Infectious Diseases, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
| | - P Villiger
- Department of Rheumatology and Clinical Immunology/Allergology, University Hospital of Bern, Bern, Switzerland
| | - L G Visser
- Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands
| | - A W de Visser
- Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands
| | - U A Walker
- Department of Rheumatology, University Hospital Basel, Basel, Switzerland
| | - C Hatz
- Department of Public Health / Division of Infectious Diseases, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland; Department of Medicine and Diagnostics, Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Switzerland; Division of Infectious Diseases & Hospital Epidemiology, Kantonsspital St. Gallen, Switzerland
| | - S Bühler
- Department of Public Health / Division of Infectious Diseases, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland; Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I. Department of Medicine University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
| |
Collapse
|
8
|
Mansilla D, Benitez MV, Gabay C, Castro M. EP1.05-11 Integrating Radiological Features to CT Guided Lung Biopsy Results; The Experience of an Argentinean University Teaching Hospital. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Gabay C, Tournour M, Bonet M, Giorlando A, Boyeras I, Thompson L, Castro M. P2.15-02 Gender-Associated Differences in Patients with Lung Cancer Treated at an Argentinean University Hospital in the Last 10 Years. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
10
|
Gabay C, Rusjan N, Martin K, Bonet M, Rojas Bilbao E, Castro M. P1.15-08 Implementation and Feasibility of the Assessment of EGFR Mutation in NSCLC Using Liquid Biopsy at an Argentinean University Hospital. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Chatzidionysiou K, Lukina G, Gabay C, Hetland ML, Hauge EM, Pavelka K, Nordström D, Canhão H, Tomsic M, Rotar Z, Lie E, Kvien TK, van Vollenhoven RF, Saevarsdottir S. Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration. Scand J Rheumatol 2018; 48:17-23. [PMID: 30260261 DOI: 10.1080/03009742.2018.1466363] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
OBJECTIVES To investigate whether smoking habits predict response to rituximab (RTX) in rheumatoid arthritis (RA). METHOD We included patients from the CERERRA international cohort receiving the first treatment cycle with available smoking status (n = 2481, smokers n = 528, non-current smokers n = 1953) and at least one follow-up visit. Outcome measures were change in Disease Activity Score based on 28-joint count (ΔDAS28) and European League Against Rheumatism (EULAR) good response at 6 months, with non-current smokers as the referent group. RESULTS Compared with non-smokers at baseline, smokers were more often rheumatoid factor (RF)/anti-citrullinated protein antibody (ACPA) positive and males, had shorter disease duration, lower DAS28 and Health Assessment Questionnaire (HAQ) score, a higher number of prior biological disease-modifying anti-rheumatic drugs, and were more likely to receive concomitant conventional synthetic disease-modifying anti-rheumatic drug (csDMARDs). Disease activity had decreased less in smokers at 6 months (ΔDAS28 = 1.5 vs 1.7, p = 0.006), although the difference was no longer significant after correction for baseline DAS28 (p = 0.41). EULAR good response rates did not differ between smokers and non-smokers overall or stratified by RF/ACPA status, although smokers had lower good response rates among seronegative patients (ACPA-negative: 6% vs 14%, RF-negative: 11% vs 18%). Smoking did not predict good response [odds ratio (OR) = 1.04, 95% confidence interval (CI) = 0.76-1.41], while ACPA, DAS28, HAQ, and concomitant csDMARDs were significant predictors for good response. However, when stratified by country, smokers were less likely to achieve good response in Sweden (unadjusted OR = 0.24, 95% CI = 0.07-0.89), and a trend was seen in the Czech Republic (OR = 0.45, 95% CI = 0.16-1.02). CONCLUSION In this large, observational, multinational RA cohort, smokers starting RTX differed from non-smokers by having shorter disease duration and lower disease activity, but more previous treatments. The overall results do not support smoking as an important predictor for response to RTX in patients with RA.
Collapse
Affiliation(s)
- K Chatzidionysiou
- a Rheumatology Unit, Department of Medicine , Karolinska University Hospital and Karolinska Institutet , Stockholm , Sweden
| | - G Lukina
- b ARBITER, Institute of Rheumatology , Moscow , Russia
| | - C Gabay
- c SCQM Registry , University Hospital of Geneva , Geneva , Switzerland
| | - M L Hetland
- d DANBIO and Copenhagen Center for Arthritis Research , Center for Rheumatology and Spine Diseases, Rigshospitalet , Glostrup , Denmark.,e Department of Clinical Medicine, Faculty of Health and Medical Sciences , University of Copenhagen , Copenhagen , Denmark
| | - E M Hauge
- f Department of Rheumatology , Aarhus University Hospital , Aarhus , Denmark
| | - K Pavelka
- g ATTRA Registry , Institute of Rheumatology , Prague , Czech Republic
| | - D Nordström
- h ROB-FIN Helsinki University Central Hospital , Helsinki , Finland
| | - H Canhão
- i CEDOC, EpiDoC Unit, NOVA Medical School and National School of Public Health , Universidade Nova de Lisboa , Lisbon , Portugal , on behalf of the Rheumatic Diseases Portuguese Register
| | - M Tomsic
- j BioRx.si University Medical Centre , Ljubljana , Slovenia
| | - Z Rotar
- j BioRx.si University Medical Centre , Ljubljana , Slovenia
| | - E Lie
- k Department of Rheumatology , Diakonhjemmet Hospital , Oslo , Norway
| | - T K Kvien
- k Department of Rheumatology , Diakonhjemmet Hospital , Oslo , Norway
| | - R F van Vollenhoven
- a Rheumatology Unit, Department of Medicine , Karolinska University Hospital and Karolinska Institutet , Stockholm , Sweden
| | - S Saevarsdottir
- a Rheumatology Unit, Department of Medicine , Karolinska University Hospital and Karolinska Institutet , Stockholm , Sweden
| |
Collapse
|
12
|
Kleinmann J, Tubach F, Le Guern V, Mathian A, Richez C, Saadoun D, Sacré K, Sellam J, Seror R, Amoura Z, Andres E, Audia S, Bader-Meunier B, Blaison G, Bonnotte B, Cacoub P, Caillard S, Chiche L, Chosidow O, Costedoat-Chalumeau N, Daien C, Daugas E, Derdèche N, Doria A, Fain O, Fakhouri F, Farge D, Gabay C, Guillo S, Hachulla E, Hajjaj-Hassouni N, Hamidou M, Houssiau F, Jourde-Chiche N, Kone-Paut I, Ladjouz-Rezig A, Lambotte O, Lipsker D, Mariette X, Martin Silva N, Martin T, Maurier F, Meckenstock R, Mekinian A, Meyer O, Mohamed S, Morel J, Moulin B, Mulleman D, Papo T, Poindron V, Puéchal X, Punzi L, Quartier P, Sailler L, Smail A, Soubrier M, Sparsa A, Tazi Mezalek Z, Zakraoui L, Zuily S, Sibilia J, Gottenberg J. Recommandations francophones, internationales et multidisciplinaires d’experts pour l’utilisation de biomédicaments dans le lupus érythémateux systémique : le groupe de travail du CRI-IMIDIATE. Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.10.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
13
|
Alpizar-Rodriguez D, Brulhart L, Müller R, Möller B, Dudler J, Ciurea A, Walker U, Von Mühlenen I, Kyburz D, Zufferey P, Mahler M, Bas S, Gascon D, Lamacchia C, Roux-Lombard P, Lauper K, Nissen M, Courvoisier D, Gabay C, Finckh A. FRI0071 Predictors for The Development of anti-Citrullinated Protein Antibodies in Individuals Genetically at Risk for Rheumatoid Arthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
14
|
Möller B, Leichtle A, Meyer P, Fiedler M, Finckh A, Kyburz D, Gabay C, Villiger P. THU0088 Iron Deficiency and Low Erythropoietin Concentrations Are Frequent Anemia Causing Factors in Rheumatoid Arthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
15
|
Brulhart L, Alpizar-Rodriguez D, Zufferey P, Bas S, Gascon D, Lamacchia C, Roux-Lombard P, Ciubotariu E, Nissen M, Gabay C, Finckh A. SAT0072 Ultrasound Is Associated with Late Phases Preceding The Clinical Onset of Rheumatoid Arthritis in Individuals Genetically at Risk. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.6084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
16
|
Alpizar-Rodriguez D, Müller R, Möller B, Dudler J, Ciurea A, Von Mühlenen I, Kyburz D, Zufferey P, Bas S, Gascon D, Lamacchia C, Roux-Lombard P, Lauper K, Courvoisier D, Gabay C, Finckh A. AB0178 Menopause Is A Predictor for The Development of Anti-Citrullinated Protein Antibodies in Women at Risk for Rheumatoid Arthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
17
|
Nissen M, Lamacchia C, Bas S, Roux-Lombard P, Courvoisier D, Kyburz D, Moeller B, Ciurea A, Mueller R, Zufferey P, Bentow C, Finckh A, Mahler M, Gabay C. FRI0088 Comparison of Rheumatoid Factor, Anti-Citrullinated Protein Antibodies, Anti-Carbamylated Protein Antibody, Anti-Peptidyl Arginine Deiminase Type-3 Antibodies and Calprotectin in Patients with Rheumatoid Arthritis and Spondyloarthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
18
|
Boutet MA, Bart G, Penhoat M, Amiaud J, Brulin B, Charrier C, Morel F, Lecron JC, Rolli-Derkinderen M, Bourreille A, Vigne S, Gabay C, Palmer G, Le Goff B, Blanchard F. Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease. Clin Exp Immunol 2016; 184:159-73. [PMID: 26701127 DOI: 10.1111/cei.12761] [Citation(s) in RCA: 190] [Impact Index Per Article: 23.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/19/2015] [Indexed: 12/11/2022] Open
Abstract
Interleukin (IL)-36α, IL-36β and IL-36γ are expressed highly in skin and are involved in the pathogenesis of psoriasis, while the antagonists IL-36Ra or IL-38, another potential IL-36 inhibitor, limit uncontrolled inflammation. The expression and role of IL-36 cytokines in rheumatoid arthritis (RA) and Crohn's disease (CD) is currently debated. Here, we observed that during imiquimod-induced mouse skin inflammation and in human psoriasis, expression of IL-36α, γ and IL-36Ra, but not IL-36β and IL-38 mRNA, was induced and correlated with IL-1β and T helper type 17 (Th17) cytokines (IL-17A, IL-22, IL-23, CCL20). In mice with collagen-induced arthritis and in the synovium of patients with RA, IL-36α, β, γ, IL-36Ra and IL-38 were all elevated and correlated with IL-1β, CCL3, CCL4 and macrophage colony-stimulating factor (M-CSF), but not with Th17 cytokines. In the colon of mice with dextran sulphate sodium-induced colitis and in patients with CD, only IL-36α, γ and IL-38 were induced at relatively low levels and correlated with IL-1β and IL-17A. We suggest that only a minor subgroup of patients with RA (17-29%) or CD (25%) had an elevated IL-36 agonists/antagonists ratio, versus 93% of patients with psoriasis. By immunohistochemistry, IL-36 cytokines were produced by various cell types in skin, synovium and colonic mucosa such as keratinocytes, CD68⁺ macrophages, dendritic/Langerhans cells and CD79α⁺ plasma cells. In primary cultures of monocytes or inflammatory macrophages (M1), IL-36β and IL-36Ra were produced constitutively, but IL-36α, γ and IL-38 were produced after lipopolysaccharide stimulation. These distinct expression profiles may help to explain why only subgroups of RA and CD patients have a potentially elevated IL-36 agonists/antagonists ratio.
Collapse
Affiliation(s)
- M-A Boutet
- INSERM, UMR 957, Nantes, France.,Laboratoire De Physiopathologie De La Résorption Osseuse, Faculté De Médecine, Université De Nantes, Nantes Atlantique Universités
| | - G Bart
- INSERM, UMR 957, Nantes, France.,Laboratoire De Physiopathologie De La Résorption Osseuse, Faculté De Médecine, Université De Nantes, Nantes Atlantique Universités.,Rheumatology Unit, Nantes University Hospital, Nantes, France
| | - M Penhoat
- INSERM, UMR 957, Nantes, France.,Laboratoire De Physiopathologie De La Résorption Osseuse, Faculté De Médecine, Université De Nantes, Nantes Atlantique Universités.,Rheumatology Unit, Nantes University Hospital, Nantes, France
| | - J Amiaud
- INSERM, UMR 957, Nantes, France.,Laboratoire De Physiopathologie De La Résorption Osseuse, Faculté De Médecine, Université De Nantes, Nantes Atlantique Universités
| | - B Brulin
- INSERM, UMR 957, Nantes, France.,Laboratoire De Physiopathologie De La Résorption Osseuse, Faculté De Médecine, Université De Nantes, Nantes Atlantique Universités
| | - C Charrier
- INSERM, UMR 957, Nantes, France.,Laboratoire De Physiopathologie De La Résorption Osseuse, Faculté De Médecine, Université De Nantes, Nantes Atlantique Universités
| | - F Morel
- EA 4331, University of Poitiers, Poitiers, France
| | - J-C Lecron
- EA 4331, University of Poitiers, Poitiers, France.,Service Immunologie/Inflammation, Poitiers University Hospital, Poitiers, France
| | | | - A Bourreille
- INSERM, UMR 913, Nantes, France.,Service d'Hépato-Gastroentérologie, Nantes University Hospital, Nantes, France
| | - S Vigne
- Division of Rheumatology, Department of Internal Medicine Specialties, University Hospitals of Geneva and Department of Pathology-Immunology, University of Geneva School of Medicine, Geneva, Switzerland
| | - C Gabay
- Division of Rheumatology, Department of Internal Medicine Specialties, University Hospitals of Geneva and Department of Pathology-Immunology, University of Geneva School of Medicine, Geneva, Switzerland
| | - G Palmer
- Division of Rheumatology, Department of Internal Medicine Specialties, University Hospitals of Geneva and Department of Pathology-Immunology, University of Geneva School of Medicine, Geneva, Switzerland
| | - B Le Goff
- INSERM, UMR 957, Nantes, France.,Laboratoire De Physiopathologie De La Résorption Osseuse, Faculté De Médecine, Université De Nantes, Nantes Atlantique Universités.,Rheumatology Unit, Nantes University Hospital, Nantes, France
| | - F Blanchard
- INSERM, UMR 957, Nantes, France.,Laboratoire De Physiopathologie De La Résorption Osseuse, Faculté De Médecine, Université De Nantes, Nantes Atlantique Universités
| |
Collapse
|
19
|
Boutet MA, Bart G, Gahier M, Amiaud J, Brulin B, Charrier C, Morel F, Lecron JC, Rolli-Derkinderen M, Boureille A, Vigne S, Gabay C, Palmer G, Goff BL, Blanchard F. A7.13 Distinct expression of IL-36α, β, γ and their antagonists IL-36RA and IL-38 in psoriasis, rheumatoid arthritis (RA) and crohn’s disease (CD). Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-209124.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
20
|
Niven J, Palmer-Lourenco G, Sattonnet-Roche P, Talabot-Ayer D, Gabay C, Gannagé M. A2.32 Macroautophagy proteins control dendritic cell activation and shape the TH1/TH17 response during antigen induced arthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-209124.67] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
21
|
Martin P, Palmer G, Rodriguez E, Seemayer CA, Talabot-Ayer D, Gabay C. A10.02 Deficiency in IL-1 receptor type 2 aggravates K/BXN serum transfer-induced arthritis in mice, but has no effect in endotoxemia. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-209124.174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
22
|
von Mühlenen I, Gabay C, Finckh A, Kuemmerle-Deschner J. NLRP3 Q703K and TNFRSF1A R92Q mutations in a patient with auto inflammatory disease. Pediatr Rheumatol Online J 2015. [PMCID: PMC4599372 DOI: 10.1186/1546-0096-13-s1-p47] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
23
|
Monnet E, Shang L, Lapeyre G, deGraaf K, Hatterer E, Buatois V, Elson G, Ferlin W, Gabay C, Sokolove J, Jones S, Choy E, McInnes I, Kosco-Vilbois M, de Min C. AB0451 NI-0101, a Monoclonal Antibody Targeting Toll Like Receptor 4 (TLR4) Being Developed for Rheumatoid Arthritis (RA) Treatment with a Potential for Personalized Medicine. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3801] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
24
|
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland M, Hauge E, Pavelka K, Gabay C, Nordström D, Canhão H, Tomsic M, van Riel P, Gomez-Reino J, Ancuta I, Kvien T, van Vollenhoven R, Saevarsdottir S. FRI0169 Smoking and Response to Rituximab in Anti-CCP Positive and Negative Rheumatoid Arthritis – Results from an International European Collaboration. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5225] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
25
|
Alpizar-Rodriguez D, Mueller R, Möller B, Dudler J, Ciurea A, Zufferey P, Kyburz D, Walker U, Von Mühlenen I, Cornelis F, Bas S, Roux-Lombard P, Gabay C, Finckh A. AB0251 Female Reproductive Factors and the Development of Anti-Citrullinated Protein Antibodies in Women at Risk of Rheumatoid Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
26
|
Walker U, Jaeger V, Chatzidionysiou K, Hetland M, Hauge EM, Pavelka K, Nordström D, Canhao H, Tomšič M, van Vollenhoven R, Gabay C. FRI0187 Rituximab Done! What's Next in Rheumatoid Arthritis? A European Observational Longitudinal Study Assessing the Effectiveness of Biologics After Rituximab Treatment in Rheumatoid Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
27
|
Petit-Teixeira E, Derbois C, Dalmasso C, Olaso R, Ambroise C, Ben Kilani M, Deleuze JF, Gabay C, Cornelis F, Finckh A. AB0004 Characterization of Putative Pre-RA Signatures by Transcriptome Analysis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.6015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
28
|
Finckh A, Yerly S, Dayer JA, Huttner A, Lazarou I, Fabreguet I, Berner J, Tapparel L, Kaiser L, Gabay C, Siegrist CA. THU0245 Post-Vaccinal Arthritis in an Ebola Vaccine Trial with a Live-Attenuated Recombinant Virus Expressing the Ebola Surface Glycoprotein (RVSV-ZEBOV). Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.6381] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
29
|
Finckh A, Neto D, Lubbeke A, Moeller B, Ciurea A, Zufferey P, Gabay C. OP0182 The Impact of Statin Use on Structural Bone Damage in Rheumatoid Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.6361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
30
|
Finckh A, Mueller R, Dudler J, Moeller B, Kyburz D, Walker U, Von Muehlenen I, Bas S, Gabay C, Bostanci N. OP0166 Antibodies Against Periodontal Pathogens are not Associated with Joint Swelling or Autoimmunity Associated with RA in a Cohort of Healthy Individuals at Increased Risk of Rheumatoid Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.6440] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
31
|
Gabay C, So A. [Soft tissue rheumatic disorders: important for general practice]. Rev Med Suisse 2015; 11:583. [PMID: 25946868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
|
32
|
Martin P, Palmer G, Rodriguez E, Woldt E, Mean I, Talabot-Ayer D, James RW, Smith D, Kwak BR, Gabay C. A5.12 Atherosclerosis severity is independent of endogenous IL-33 signalling. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-207259.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
33
|
Niven J, Palmer-Lourenco G, Talabot-Ayer D, Gabay C, Gannagé M. A1.23 Macroautophagy deficiency in dendritic cells exacerbates antigen-induced arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-207259.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
34
|
Gabay C, Riek M, Hetland M, Hauge E, Pavelka K, Tomsic M, Canhao H, Chatzidionysiou K, van Vollenhoven R, Lukina G, Nordström D, Lie E, Ancuta I, Loza Santamaria E, van Riel P, Kvien T. SAT0036 Retention of Tocilizumab Therapy: A Comparison between Tocilizumab in Monotherapy and in Combination with DMARDS Based on the Tocerra Collaboration. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2806] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
35
|
von Mühlenen I, Finckh A, Roux-Lombard P, Gabay C. AB0698 Overlaping Spondylarthritis and Periodic Autoinflammatory Syndrome? A “Bed to Bench” Story. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
36
|
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland M, Tarp U, Pavelka K, Gabay C, Nordström D, Canhão H, Tomsic M, van Riel P, Gomez-Reino J, Ancuta I, Kvien T, van Vollenhoven R. SAT0229 Effectiveness of Repeated Courses of Rituximab in RA – Results from the Cererra Collaboration. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
37
|
Gabay C, McInnes I, Kavanaugh A, Tuckwell K, Collinson N, Klearman M, Green J, Sattar N. OP0165 Changes in Lipoprotein(A) after Treatment with Tocilizumab (TCZ), Adalimumab (ADA), and Methotrexate (MTX) in Patients with Rheumatoid Arthritis (RA). Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
38
|
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland M, Tarp U, Pavelka K, Gabay C, Nordström D, Canhão H, Tomsic M, van Riel P, Gomez-Reino J, Ancuta I, Kvien T, van Vollenhoven R. FRI0328 Fixed versus On-Flare Retreatment with Rituximab in RA – Results from the Cererra Collaboration. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
39
|
Finckh A, Debost-Legrand A, Müller R, Möller B, Dudler J, Ciurea A, Walker U, Zufferey P, Kyburz D, Bas S, Dubost JJ, Crevaux I, Von Mühlenen I, Soubrier M, Cornelis F, Gabay C, Migliorini P. THU0238 Risk Factors for the Development of Anti-Citrullinated Protein Antibodies in Individuals Genetically at Risk for RA. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.5178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
40
|
Gabay C, Hasler P, Kyburz D, So A, Villiger P, von Kempis J, Walker U. Biological agents in monotherapy for the treatment of rheumatoid arthritis. Swiss Med Wkly 2014; 144:w13950. [PMID: 24723273 DOI: 10.4414/smw.2014.13950] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease, which results in joint destruction and permanent disability. The advent of disease-modifying antirheumatic drugs (DMARDs) has made a profound impact on the outcome and prognosis of RA. Methotrexate (MTX) is a central agent in RA therapy, and is used either alone or in combination with biological DMARDs. However, a large proportion of RA patients (20%-40%) either do not respond to or are unable to tolerate MTX or the alternative agents used in place of MTX (including leflunomide, sulfasalazine, azathioprine, hydroxycholoquine and combination DMARDs). For these patients, monotherapy with biological DMARDs is a key treatment option that balances tolerability with improved clinical outcomes. This article reviews the data for four biological agents approved for use as monotherapy in Switzerland (adalimumab, certolizumab pegol, etanercept and tocilizumab) in order to formulate a consensus statement on their roles in biologic monotherapy of RA.
Collapse
Affiliation(s)
- C Gabay
- University Hospitals of Geneva, 26 Avenue Beau-Séjour, 1211, Geneva 14, SWITZERLAND;
| | | | | | | | | | | | | |
Collapse
|
41
|
Berner J, Gabay C. [Best practice use of corticosteroids in rheumatoid arthritis]. Rev Med Suisse 2014; 10:603-608. [PMID: 24701713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Since the 50s oral glucocorticoids including prednisone are used in the management of rheumatoid arthritis due to their efficacy and the limited availability of the other treatments in the past. Thereafter numerous studies confirmed the usefulness of prednisone in controlling clinical inflammatory manifestations and the progression of radiographic damage. Sixty years later the position of prednisone in the treatment strategy of rheumatoid arthritis is still controversial, considering the presence of numerous side effects and the availability of other effective treatments. If prednisone can be reasonably used in some situations either as bridging therapy in combination with other treatments or in case of flare, its long-term use should be avoided.
Collapse
|
42
|
Court S, Nissen MJ, Gabay C. [Pigmented villonodular synovitis]. Rev Med Suisse 2014; 10:609-615. [PMID: 24701714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Pigmented villonodular synovitis (PVNS), also known as tenosynovial giant cell tumour is an articular pathology that occurs predominantly in young adults and is caused by an abnormal proliferation of the synovial membrane. The clinical presentation includes pain and joint swelling. MRI represents the best imaging modality to investigate this disease but the histopathology of synovial tissue provides the definitive diagnosis. The management of PVNS is often difficult due to the high risk of relapse after treatment. The objective of this article is to review the literature regarding the diagnosis and therapy of this poorly understood condition.
Collapse
|
43
|
Luong Ba K, Gabay C. [Disease modifying antirheumatic drugs]. Rev Med Suisse 2014; 10:595-602. [PMID: 24701712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
The natural history of rheumatoid arthritis, previously burdened with high morbidity, has been strongly modified by appropriate treatment. Early diagnosis and treatment, and follow-up by a specialist, with the aim to achieve remission or low disease activity, are essential for the functional outcome of patients. Disease-modifying anti-rheumatic drugs include "conventional" treatments like methotrexate, biologic therapies such as TNF-inhibitors, abatacept, tocilizumab and rituximab, and targeted synthetic therapies such as tofacitinib (a JAK kinase inhibitor). New treatments currently under study should allow rheumatologists to successfully treat even more patients than nowadays.
Collapse
|
44
|
So A, Gabay C. [The state of rheumatoid arthritis, 2014]. Rev Med Suisse 2014; 10:579. [PMID: 24701708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
|
45
|
Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Klearman M, Musselman D, Agarwal S, Green J, Kavanaugh A. LB0003 Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 adacta trial:. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2012-eular.1963] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
46
|
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland M, Tarp U, Ancuta I, Pavelka K, Nordström D, Gabay C, Canhao H, Tomsic M, van Riel P, Gomez-Reino J, Kvien T, van Vollenhoven R. THU0086 Seropositivity and response to RTX: Data from the cererra collaboration:. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2012-eular.2051] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
47
|
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland M, Tarp U, Ancuta I, Pavelka K, Nordström D, Gabay C, Canhao H, Tomsic M, van Riel P, Gomez-Reino J, Kvien T, van Vollenhoven R. OP0028 Efficacy of different doses of rituximab for the treatment of RA: Data from the cererra collaboration. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2012-eular.1711] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
48
|
Holzinger D, Nippe N, Marketon K, Dalbeth N, Merriman T, Baeten D, Busso N, Vogl T, Foell D, Gabay C, Roth J. OP0099 Toll-like receptor 4 agonists MRP 8 and MRP 14 act as endogenous enhancers of MSU-crystal induced IL-1 secretion in vitro and reflect disease activity in gout patients in vivo. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2012-eular.1782] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
49
|
Affiliation(s)
- M J Nissen
- Division of Rheumatology, Geneva University Hospital, , Geneva, Switzerland
| | | | | | | | | |
Collapse
|
50
|
Holzinger D, Nippe N, Vogl T, Marketon K, Mysore V, Weinhage T, Dalbeth N, Pool B, Merriman T, Baeten D, Ives A, Bagnoud N, Busso N, Foell D, Bas S, Gabay C, Roth J. OR6-004 – MRP8/14 promote MSU-crystal induced inflammation. Pediatr Rheumatol Online J 2013. [PMCID: PMC3952172 DOI: 10.1186/1546-0096-11-s1-a99] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|